Table 3.
Antimicrobial resistance in predominant isolates of Gram-negative bacterial neonatal sepsis.
| K. pneumoniae, n/N (%) | E. coli, n/N (%) | |
|---|---|---|
| Ampicillin | 103/104 (99.0) | 64/92 (69.6) |
| Ampicillin/sulbactam | 93/102 (91.2) | 14/94 (14.9) |
| Amoxicillin/clavulanate | 74/107 (69.2) | 4/84 (4.8) |
| Piperacillin | 92/102 (90.2) | 53/85 (62.4) |
| Piperacillin/tazobactam | 69/116 (59.5) | 3/104 (2.9) |
| Cefazolin | 103/110 (93.6) | 41/63 (65.1) |
| Cefoxitin | 7/24 (29.2) | 0/16 (0.0) |
| Cefuroxime | 30/35 (85.7) | 14/22 (63.6) |
| Cefotaxime | 95/99 (96.0) | 28/77 (36.4) |
| Ceftazidime | 94/114 (82.5) | 15/103 (14.6) |
| Ceftriaxone | 30/38 (78.9) | 18/35 (51.4) |
| Cefoperazone/sulbactam | 10/23 (43.5) | 2/12 (16.7) |
| Cefepime | 98/115 (85.2) | 29/102 (28.4) |
| Chloromycetin | 21/83 (25.3) | 5/71 (7.0) |
| Trimethoprim/sulfamethoxazole | 53/111 (47.7) | 47/91 (51.6) |
| Ciprofloxacin | 8/109 (7.3) | 25/97 (25.8) |
| Moxifloxacin | 2/43 (4.7) | 12/40 (30.0) |
| Levofloxacin | 2/112 (1.8) | 24/100 (24.0) |
| Norfloxacin | 2/11 (18.2) | 2/5 (40.0) |
| Gentamicin | 35/110 (31.8) | 34/101 (33.7) |
| Tobramycin | 7/34 (20.6) | 6/23 (26.1) |
| Amikacin | 2/113 (1.8) | 1/97 (1.0) |
| Meropenem | 22/94 (23.4) | 1/82 (1.2) |
| Imipenem | 31/109 (28.4) | 1/97 (1.0) |
| Ertapenem | 2/18 (11.1) | 0/20 (0.0) |
| Tetracycline | 55/105 (52.4) | 53/79 (67.1) |
| Tigecycline | 0/22 (0.0) | 0/12 (0.0) |
| Minocycline | 1/10 (10.0) | 2/9 (22.2) |
| Aztreonam | 94/111 (84.7) | 28/96 (29.2) |
| Polymyxin B | 0/22 (0.0) | 0/7 (0.0) |
n, number of resistant isolates; N, number of tested.